Why drugs go into shortage
Here's the paradox that surprises everyone: US drug shortages almost never hit expensive new brands. They hit the cheapest, oldest generics — the sterile injectables that hospitals can't function without. Understanding why is the key to spotting the next one coming.
It's an economics problem, not a chemistry problem
When a generic's price collapses after the patent cliff, the margin gets razor-thin. That has predictable effects:
- Fewer companies want to make a drug they barely profit on, so the number of manufacturers shrinks — sometimes to a single source.
- No one wants to invest in upgrading an aging factory line for a product that earns pennies a dose.
- Manufacturing gets concentrated in a few plants, often overseas, to squeeze out cost.
Now the system is brittle. One problem at one plant, and there's no slack anywhere else to absorb it.
Why sterile injectables are the usual victims
Injectable drugs — the ones given in a hospital — are structurally fragile. Sterile manufacturing is difficult and unforgiving: a contamination problem can shut a whole line for months, and there are only a handful of facilities in the world qualified to make many of them. Combine “hard to make” with “barely profitable” and you get the shortage-prone corner of the market.
The triggers that tip it over
- Quality problems: an FDA inspection finds issues, or a batch is recalled, and production stops.
- A manufacturer exits: a company simply stops making a money-losing drug, and if it was one of only two suppliers, the other can't cover the gap.
- A demand spike: a competitor's shortage doubles everyone else's orders overnight.
- Raw-material disruptions: a problem with the active ingredient supplier upstream, often in a single country.
A leading indicator hiding in the price
Sustained price deflation is an early warning: a generic driven too cheap is a generic manufacturers are about to abandon. It often shows up in the pricing data before the shortage does — which is why falling price is one of the factors in our fragility score.
What happens on the ground
When a drug goes short, pharmacies and hospitals ration it, compound their own when they legally can, or switch patients to a therapeutic alternative — each of which carries its own risk and cost. For critical oncology and emergency drugs, a shortage isn't an inconvenience; it changes care.
Seeing it before it breaks
This is the whole thesis of DrugDashboards. By watching manufacturer counts, price trends, recalls, and shortage filings together, you can spot a drug drifting toward fragility while there's still time to plan. Browse the most fragile drugs or the current shortage list to see it live.